Trial
NCT03790111
A Safety and Efficacy Study of XERMELO® + First-line Chemotherapy in Patients With Advanced Biliary Tract Cancer
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
TerSera Therapeutics LLC
Collaborators
—
Condition
Biliary Tract Cancer (BTC)
Intervention
telotristat ethyl
Why stopped
Did not meet pre-specified Progression-Free Survival at Month 6 for Stage 2 Analysis
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-04-19